PHARMACEUTICAL 2022

Tuhura Biosciences Inc NV
Rank 442 of 471



PHARMACEUTICAL 2022

Tuhura Biosciences Inc NV
Rank 442 of 471

The relative strengths and weaknesses of Tuhura Biosciences Inc NV are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tuhura Biosciences Inc NV compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 21% points.The greatest weakness of Tuhura Biosciences Inc NV is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 168% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	11,793
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,780
Liabilities, Non-Current	0
Other Assets	1,600
Other Compr. Net Income	0
Other Expenses	16,594
Other Liabilities	182
Other Net Income	-132
Other Revenues	0
Property and Equipment	150
Research and Development	11,815
Selling, General and Administrative Expense	9,757

Output Variable	Value in 1000 USD
Assets	13,543
Liabilities	2,962
Expenses	38,166
Revenues	0
Stockholders Equity	10,581
Net Income	-38,298
Comprehensive Net Income	-38,298
BaseVar	27,402
ECR before LimitedLiability	-185%
Economic Capital Ratio	107%